Aripiprazole once-monthly for treatment of schizophrenia: Double-blind, randomised, non-inferiority study

British Journal of Psychiatry

Volumn 205, Issue 2, 2014, Pages 135-144

  Fleischhacker, W Wolfgang ^a   Sanchez, Raymond ^b   Perry, Pamela P ^b   Jin, Na ^b   Peters Strickland, Timothy ^b   Johnson, Brian R ^b   Baker, Ross A ^b   Eramo, Anna ^c   McQuade, Robert D ^b   Carson, William H ^b   Walling, David ^d   Kane, John M ^e,f  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c LUNDBECK RESEARCH USA   (United States)

^d Collaborative NeuroScience Network Inc ^*  (United States)

^e ZUCKER HILLSIDE HOSPITAL   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903896379     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.113.134213     Document Type: Article

References (24)

1. Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007; 22: 275-82. (Pubitemid 47237546)
2. Patel MX, De Zoysa N, Bernadt M, David A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009; 23 : 789-96.
3. Kane J, Sanchez R, Perry P, Jin N, Johnson BR, Forbes RA, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind, placebo-controlled study. J Clin Psych 2012; 73: 617-24.
4. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-9. (Pubitemid 34680462)
5. Croxtall JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs 2012; 26: 155-83.
6. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76. (Pubitemid 18039085)
7. Guy W. ECDEU Assessment Manual for Psychopharmacology - Revised. US Department of Health Services, 1976.
8. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, doubleblind, placebo-controlled study. Schizophr Res 2010; 116: 107-17.
9. Mallikaarjun S, Kane JM, Bricmont P, McQuade R, Carson W, Sanchez R, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res 2013; 150: 281-8.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, revised) (DSM-IV-TR). APA, 2000.
11. Andreasen NC, Carpenter WT, Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-9. (Pubitemid 40343909)
12. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-9.
13. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6. (Pubitemid 19154942)
14. Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, et al. Columbia Suicide Severity Rating Scale. The Research Foundation for Mental Hygiene, Inc, 2008 (http://cssrs.columbia.edu/docs/C-SSRS-1-14-09-Baseline.pdf).
15. Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain 2003; 4: 407-14. (Pubitemid 37122581)
16. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125-32. (Pubitemid 41070972)
17. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048-56. (Pubitemid 37158250)
18. Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res 2008; 98: 318-22. (Pubitemid 350235891)
19. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6: 325-37. (Pubitemid 38146250)
20. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013; 14: 2-44.
21. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011; 168: 603-9.
22. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011; 364: 842-51.
23. Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013; 74: 568-75.
24. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2014; 40: 192-213.